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Purpose: Vascular endothelial growth factor (VEGF) is the most potent angiogenic mitogen, and has been associated
with angiogenesis. Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains, which can
induce VEGF expression. The aims of the present study were to evaluate the heparanase expression and its relationship
with VEGF in the retina of oxygen-induced retinopathy (OIR) mice, and to investigate the effect of the heparanase inhibitor
phosphomannopentaose sulfate (PI-88) in the OIR retinas.
Methods: Seventy-seven newborn C57BL/6 mice were involved in this study. On postnatal day 7 (P7), pups were exposed
to a hyperoxia condition (75% oxygen) for 5 days, and on P12, the mice were returned to room air. Control mice were
exposed  to  room  air  from  birth  until  P17,  with  normally  developing  retinal  vasculature.  PI-88  was  administered
intraperitoneally to OIR mice at a dose of 35.7 mg/kg/day for 5 consecutive days. The expression level of heparanase and
VEGF in the retinas was assayed using immunohistochemistry, Q-RT–PCR, and western blot.
Results: The expression levels of heparanase and VEGF were increased in the OIR retinas compared with the control
mice. The Q-RT–PCR results showed that the mRNA expression levels of heparanase and VEGF in OIR retina were
increased 1.71 fold (p<0.0001) and 4.34 fold (p<0.0001), respectively. The western blot results showed that the protein
expression levels of heparanase and VEGF were increased 1.49 fold (p<0.0001) and 1.72 fold (p<0.0001), respectively,
in the OIR retinas compared with the normal retinas. The immunohistochemistry analysis revealed that the heparanase
and VEGF signals were intense in the retinal vascular endothelia of the OIR mice but faint in those of the normal controls.
The increased protein and mRNA expression levels of heparanase and VEGF in the mouse retinas were significantly
decreased by PI-88 administration (p<0.0001).
Conclusions: Heparanase expression was upregulated and correlated with an increase in VEGF expression in the OIR
mouse retinas, and might be involved in the progress of retinopathy of prematurity. Inhibition of heparanase expression
by PI-88 could be used as a novel therapeutic method for retinopathy of prematurity.
Retinopathy of prematurity (ROP) is one of the leading
causes  of  blindness  in  children  worldwide,  although
considerable  progress  has  recently  been  made  in  surgical
strategies [1]. It is estimated that each year, 3,400 infants
suffer from ROP-related visual impairments and 650 will
become blind [2,3]. ROP is characterized by pathological
ocular  angiogenesis  or  retinal  neovascularization  (NV),
mostly by exposure of low-birthweight infants to hyperbaric
oxygen to maintain arterial oxygen tension in an appropriate
range [4]. Nevertheless, the specific mechanism leading to
ROP remains unknown and is difficult to study in human
infants.  Many  molecules  are  involved  in  angiogenesis,  of
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which vascular endothelial growth factor (VEGF) is one of
the best studied. VEGF stimulates the elongation of epithelial
cells  and  subsequently  can  induce  the  formation  of  new
vessels [5].
Heparanase is an endoglycosidase that degrades heparan
sulfate  (HS)  in  the  extracellular  matrix  (ECM)  and  cell
surface, and plays significant roles in cancer metastasis and
angiogenesis [6]. Heparan sulfate proteoglycans (HSPGs) are
macromolecules consisting of a protein core to which HS
chains are linked [7]. HSPGs are present on the membranes
of  eukaryotic  cells  (i.e.,  syndecans  and  glypicans)  or  as
molecules that are secreted into the ECM (i.e., perlecans). HS
chains  bind  a  large  variety  of  molecules,  such  as  ECM
structural proteins, growth factors, chemokines, and enzymes,
thereby participating in central biologic processes, including
adhesion,  proliferation,  survival,  and  differentiation  [7,8].
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1649Therefore, cleavage of HS side chains is expected to not only
alter the integrity of the extracellular matrix but also release
HS-bound  growth  factors,  chemokines,  and  cytokines.
Meanwhile,  HS  fragments  can  modulate  the  activities  of
growth factors such as basic fibroblast growth factor and
VEGF [9–11]. In addition, heparanase is actively involved in
regulating  VEGF  gene  expression  via  c-Src  activation  to
promote angiogenesis [12].
Phosphomannopentaose  sulfate  (PI-88)  is  a  synthetic
polysulfated oligosaccharide that inhibits the activity of the
extracellular  matrix–degrading  enzyme  heparanase  [13].
PI-88 is a 2-kDa heparan sulfate mimetic structurally distinct
from  heparin,  which  is  a  heterogeneous  mixture  of
polysaccharide  chains  of  varying  lengths  with  molecular
weights of 3 to 30 kDa. PI-88 was primarily developed as an
antitumor agent and can potently inhibit tumor metastasis and
angiogenesis [13–16]. Additionally, human and mammalian
toxicology  studies  have  demonstrated  that  PI-88  is  well
tolerated and has low anticoagulant activity [17]. PI-88 is
currently  in  Phase  II  and  III  clinical  trials  to  assess  its
therapeutic potential as an anticancer drug [14,18].
However, it is unknown whether heparanase is involved
in ROP and contributes to angiogenesis, whether heparanase
expression is closely related to VEGF expression in ROP, and
whether heparanase could become a new therapeutic target for
ROP.  In  this  study,  we  investigated  an  oxygen-induced
retinopathy  (OIR)  mouse  model  to  try  to  answer  these
questions.
METHODS
Induction of oxygen-induced retinopathy and treatment: The
studies were approved by the animal care and use committee
of Zhongshan Ophthalmic Center, Sun Yat-Sen University.
We adopted the standard OIR model as described previously
[19]. Seventy-seven specific pathogen free (SPF) newborn
C57BL/6 mice were obtained from the Traditional Chinese
Medicine Center for Animals of Guangzhou University. Food,
water, light, temperature, and other conditions were the same
for all animals. These mice were randomly divided into three
groups: Group A, the control group (normal mice, n=25), was
reared  in  the  standard  SPF  level  for  the  duration  of  the
experiment. Group B was the OIR model group (OIR mice,
n=26).  Group  C  was  OIR  mice  receiving  PI-88  (Progen
Industries Limited, Brisbane, Australia) (dissolved in sterile
phosphate-buffered saline, PBS, pH 7.4) at a dose of 37.5 mg/
kg/d  intraperitoneally  for  5  consecutive  days  (OIR  mice
+PI-88, n=26).
Mouse model of oxygen-induced retinopathy and treatment:
The  OIR  mouse  model  was  established  as  described
previously [19]. Briefly, Group B and Group C mice were
placed with their nursing mothers in the same covered plastic
box with 75% oxygen from P7 (postnatal day 7) through P12.
The oxygen was delivered at 75±2% and was checked at least
three times daily during the oxygen exposure period. The
oxygen concentration was measured with an Oxygen Monitor
(BioSpherix, Ltd., New York, NY). On P12, the animals were
returned to room air for 5 days (P17). The Group C mice were
injected  with  PI-88  at  a  dose  of  35.7  mg/kg/day
intraperitoneally for 5 consecutive days. Finally, all 77 mice
were euthanized using a lethal intraperitoneal injection of
chloral hydrate (360 mg/kg) at P17. The retinal tissues of all
77 mice were used for immunohistochemistry, Q-RT–PCR,
and western blotting.
Fluorescein  isothiocyanate–dextran  (FITC-Dextran)
perfusion of the retinal blood vessels: To study the retinal
vascular  pattern,  systemic  perfusion  was  performed  using
FITC-dextran (Sigma, St. Louis, MO) and polyphosphate-L-
lysine  (Sigma)  in  paraformaldehyde  (PFA;  Sigma).  The
animals were given a dose of 3 ml/kg chloral hydrate for
anesthesia, and a median sternotomy was performed. The left
ventricle of the heart was identified and perfused with 0.5 ml
4%  PFA  (50  mg/ml  FITC-dextran  and  10  mg/ml
polyphosphate-L-lysine in 4% PFA) using a 1-ml tuberculin
syringe with a 26-gauge needle for less than 30 s, until a
yellowing of the liver was observed. The eyes of each mouse
were then enucleated. Eyes were placed in 4% PFA for 30
min. Under a dissecting microscope (Axioplan2, ZEISS, Inc.,
Oberkochen,  Germany),  the  retina  was  removed  and  flat-
mounted by making radial cuts. Each retina was imaged with
a fluorescence microscope (Axiovert100, ZEISS, Inc.).
Immunohistochemistry staining for heparanase and vascular
endothelial  growth  factor  in  oxygen-induced  retinopathy
retinas: Immunohistochemistry was performed as previously
described,  with  minor  modifications  [20].  Deparaffinized
retinal sections were blocked in 3% hydrogen peroxide and
5% BSA (Sigma). Retinal sections were incubated overnight
at 4 °C with polyclonal rabbit anti-rat heparanase-1 antibody
(1:1,000;  Abcam,  Cambridge,  MA)  and  VEGF  antibody
(1:1,000; Abcam). After being washed with PBS 3 times,
sections  were  incubated  with  horseradish  peroxidase–
conjugated goat antirabbit immunoglobulin G (Invitrogen,
Carlsbad,  CA).  Color  was  developed  using  a  3,3′-
diaminobenzidine kit (Vector Laboratories, Burlingame, CA)
for  5  min,  followed  by  counterstaining  with  Mayer’s
hematoxylin.  Immunostaining  intensity  was  quantitatively
analyzed  using  Image-Pro  Plus  software  (version  5.1  for
Windows; Media Cybernetics, Bethesda, MD) [21,22].
Real-time  polymerase  chain  reaction  analysis  for  the
expression of heparanase and vascular endothelial growth
factor in oxygen-induced retinopathy retinas: We extracted
total RNA from retinas harvested from the different groups
using TRIzol (Invitrogen). The concentration and purity of the
RNA were determined with a spectrophotometer. The RNA
was purified using Amplification Grade DNase I (AMPD1;
Sigma), and reverse transcriptase (PrimeScript RT reagent
Kit,  DRR037A;  TaKaRa,  Shiga,  Japan)  was  used  to
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SYBR Green Real-Time PCR Master Mix (SYBR Premix Ex
Taq kit; TaKaRa), and gene expression was measured using
SYBR green II (Qiagen, Hilden, Germany) with the ABI
PRISM7000 real-time (Life Technologies Co., Ltd., Carlsbad,
CA) PCR system. The PCR primers used to detect VEGF,
heparanase, and 18S rRNA were as follows: heparanase sense
strand: 5′-CTC GAA GAA AGA CGG CTA AGA-3′, and
reverse strand: 5′-TGG TAG CAG TCC GTC CAT T-3′;
VEGF sense strand: 5′-AAG GAG AGC AGA AGT CCC
ATG A-3′, and reverse strand: 5′-CAC AGG ACG GCT TGA
AGA TGT-3′; 18S rRNA sense strand: 5′-TTC CGA TAA
CGA ACG AGA CTC T-3′ and reverse strand: 5′-TGG CTG
ACA CGC CAC TTG TC-3′.
Western  blot  assay  for  the  expression  of  heparanase  and
vascular  endothelial  growth  factor  in  oxygen-induced
retinopathy retinas: Harvested retinas were homogenized in
150 µl lysis buffer containing 50 mM Tris-HCl (pH 6.8),
150  mM  NaCl,  0.5%  Triton  X-100,  and  10  µl  protease
inhibitor cocktail (Sigma-Aldrich, Inc., St. Louis, MO), and
then centrifuged at 15,000× g at 4 °C for 30 min. Supernatants
were collected and mixed with 5× sample loading buffer to
prepare  samples.  Samples  were  electrophoresed  on  12%
sodium dodecyl sulfate gels and subsequently transferred to
polyvinylidene  difluoride  membranes  (Bio-Rad,  Hercules,
CA). Each membrane was blocked with 5% skim milk in Tris-
buffered  saline  containing  0.5%  Tween-20  at  room
temperature for 1 h. Next, the membranes were incubated with
polyclonal rabbit antihuman heparanase-1 antibody (1:1,000)
and  polyclonal  rat  antihuman  β-actin  antibody  (1:1,000;
Abcam)  at  4  °C  overnight.  The  heparanase-1  antibody
recognizes primarily the 50 kDa active form of the enzyme.
The β-actin antibody recognizes primarily the 42 kDa active
form of the enzyme. The membranes were then incubated with
a secondary antibody at room temperature for 1 h. Finally, the
blots  were  developed  by  a  chemiluminescence  kit  (Cell
Signaling Technology Inc., Danvers, MA). Semiquantitative
analysis was performed by measuring the optical densities of
the bands.
Statistical  analysis:  Data  are  presented  as  mean±standard
deviation  (SD).  Statistical  significance  was  analyzed  with
one-way ANOVA using GraphPad Prism 4.0 software system
(GraphPad,  San  Diego,  CA)  and  the  statistical  software
program SPSS 16.0 for Windows (Chicago, IL). P values of
<0.05 were considered significant in all cases.
RESULTS
Fluorescein isothiocyanate-Dextran systemic perfusion: To
determine whether the OIR mouse model was successfully
established,  FITC-dextran  perfusion  of  the  retinal  blood
vessels was observed under a fluorescent microscope in P17
OIR retinas. As shown in Figure 1A, fluorescence images
showing  retinal  vessels  were  tortuous  and  expanded  in
volume. Capillary hemangioma was ob-served, and retinal
vascular morphology exhibited abnormal distribution at the
junction of the perfused area and non-infused area. Significant
expansion of large vessels, large avascular area, and extensive
angiogenesis  were  observed.  Thus,  the  OIR  model  was
successfully established (Figure 1B).
Immunohistochemistry  staining  analyses:  In  the  present
study, the expression levels of heparanase and VEGF were
increased in OIR retinal vascular endothelial cells (Figure
2B,E). Meanwhile, the expression levels of heparanase and
VEGF were decreased in response to PI-88 treatment. Positive
cells were stained red, and cytoplasmic staining was clearly
observed in the retinal cells (Figure 2C,F). As shown in Figure
2B-F, the staining for heparanase and VEGF was intense in
the endothelia of blood vessels in the OIR retinas but faint in
those of normal retinas and OIR+PI-88 retinas.
Quantitative  analysis  of  immunostaining  fluorescence
intensity  showed  that  in  vascular  endothelial  cells,  the
heparanase  expression  was  increased  in  the  OIR  retinas
compared with the normal retinas (p=0.003), and decreased
in  the  PI-88-treated  OIR  retinas  compared  with  the  OIR
retinas (p=0.001; Figure 2G). In vascular endothelial cells, the
VEGF expression was significantly increased in the retinas of
Group B compared with those of Group A (p<0.0001) and
decreased in Group C compared with Group B (p=0.001;
Figure 2H).
Real-time polymerase chain reaction analysis: We used real-
time PCR to determine if the mRNA expression levels of
heparanase  and  VEGF  were  changed  in  retinal  vascular
endothelial cells in OIR mice. The results indicated that the
expression levels of heparanase and VEGF mRNAs increased
in the OIR mice compared with Group A and Group C. In
contrast,  the  expression  of  heparanase  and  VEGF  was
decreased by treatment with PI-88 (Group C). As shown in
Figure  3A,  the  mRNA  expression  level  of  heparanase
increased  1.71  fold  in  Group  B  compared  with  Group  A
(p<0.0001), and the mRNA expression level of heparanase
decreased  2.18  fold  in  Group  C  compared  with  Group  B
(p<0.0001).  There  were  significant  differences  in  the
heparanase  expression  level  among  the  three  groups
(p<0.0001). Compared with Group A, the mRNA expression
level of VEGF increased 4.34 fold in Group B (p<0.0001),
Compared  with  Group  B,  the  mRNA  expression  level  of
VEGF decreased 2.00 fold in Group C (p<0.0001). There were
significant differences in the VEGF expression level among
the three groups (p<0.0001; Figure 3B).
Western blotting: We used western blotting to investigate if
the  protein  expression  levels  of  heparanase  and  VEGF
changed in the retinal vascular endothelial cells in the OIR
mice.  Western  blot  analysis  for  heparanase  and  VEGF
demonstrated that the protein expression levels of heparanase
and  VEGF  in  the  OIR  mice  increased  (Figure  4A,B).
Compared  with  Group  A,  the  protein  expression  level  of
heparanase  increased  1.49  fold  in  Group  B  (p=0.000),
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1651Compared  with  Group  B,  the  protein  expression  level  of
heparanase decreased 1.44 fold in Group C (p=0.000). There
were  significant  differences  in  the  heparanase  protein
expression among the three groups (p<0.0001; Figure 4C).
Additionally, compared with Group A, the protein expression
level of VEGF increased 1.72 fold in Group B (p<0.0001).
Compared  with  Group  B,  the  protein  expression  level  of
VEGF decreased 1.14 fold in Group C (p<0.0001). There were
Figure  1.  Fluorescein  isothiocyanate-
dextran (FITC) perfusion of the retinal
blood  vessels  was  observed  under  a
fluorescent microscope in postnatal day
17  (P17)  oxygen-induced  retinopathy
(OIR) retinas. A: Mice were perfused
with FITC-labeled fluorescein sodium
in  normal  oxygen  pressure.  B:  Mice
were  perfused  with  FITC-labeled
fluorescein  sodium  in  hypoxia.
Fluorescence  images  showing  retinal
vessels were tortuous and expanded in
volume.  Capillary  hemangioma  was
observed,  and  retinal  vascular
morphology  exhibited  abnormal
distribution  at  the  junction  of  the
perfused  area  and  non-infused  area.
Significant expansion of large vessels,
large  avascular  area,  and  extensive
angiogenesis were observed. There are
non-vascular area and neovascular tuffs
in  oxygen-induced  retinopathy  (OIR)
mice (arrow).
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1652significant differences in the VEGF protein expression among
the three groups (p<0.0001; Figure 4D).
DISCUSSION
In  the  present  study,  we  demonstrated  that  heparanase
expression was significantly increased in the retinal vascular
endothelia of OIR mice but there was faint staining in normal
mice.  Heparanase  is  an  endoglycosidase  that  degrades
heparan sulfate glycosaminoglycan, leading to the loss of
basement  membrane  integrity  and  the  release  of  heparan
sulfate–bound  angiogenic  and  growth-promoting  factors
[23],  which  subsequently  stimulate  tumor  blood  vessel
growth,  cellular  invasion,  migration,  adhesion,  metastasis,
differentiation,  and  proliferation  [24–26].  Heparanase  is
overexpressed  in  a  variety  of  tumors  [27–32],  corneal
neovascularization [33], and the diabetic rat retina [34]. These
findings suggest that heparanase expression is active in the
vessel endothelium of newborn mouse retinas impaired by
Figure 2. The effects of Immunohistochemistry staining for retina sections were accessed in this study. A-C: The retina sections stained for
heparanase positive cells were show. A: It shows a normal mouse retina section on postnatal day 17 (P17). B: It displays the retina section in
oxygen-induced retinopathy (OIR) mice. C: It shows PI-88 treatment of an OIR mouse retina. In all of the sections, the red arrow points to
heparanase positive cells. D-F: The retina sections stained for vascular endothelial growth factor (VEGF) positive cells were show. D: It shows
a normal mouse retina section on P17. E: It displays the retina section in OIR mice; F: It shows phosphomannopentaose sulfate (PI-88)
treatment of an OIR mice retina. In all of the sections, the red arrow points to VEGF positive cells. G: The percentages of heparanase-positive
cells in retina tissue by immunohistochemistry were as follows: The percentage of Group A was 32.00±7.00; the percentage of Group B was
51.33±1.53; the percentage Group C was 32.00±3.61. H: The percentages of VEGF-positive cells in retina tissue by immunohistochemistry
were as follows: The percentage of Group A was 65.00±2.00. The percentage of Group B was 101.33±10.11; The percentage Group C was
19.00±2.65. The differences among groups were significant (p<0.0001).
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1653hyperoxia. Endothelial cells are an important cellular source
of heparanase enzymatic activity [35–37].
Along  with  the  high  expression  of  heparanase,  the
expression  of  VEGF  was  also  enhanced  in  OIR  mice,  as
previously reported. Zetser et al. [12] reported that heparanase
is  actively  involved  in  regulating  VEGF  gene  expression.
Heparanase expression is upregulated and is associated with
increased VEGF expression in other retinopathy models, such
as diabetic rats [34]. A novel mechanistic pathway driven by
heparanase expression in myeloma cells can induce elevated
levels of VEGF and shedding of syndecan-1 from matrix-
anchored complexes that together activate integrin and VEGF
receptors on adjacent endothelial cells, thereby stimulating
tumor  angiogenesis  [38].  Cohen-Kaplan  et  al.  [39]
demonstrated that heparanase overexpression by epidermoid,
breast, melanoma, and prostate carcinoma cells can induce a
three- to fivefold elevation in VEGF C expression in vitro, and
heparanase  gene  silencing  was  associated  with  decreased
VEGF  C  levels.  Heparanase  also  seems  to  be  actively
involved  in  regulating  VEGF  gene  expression  via  c-Src
activation to promote angiogenesis [9]. Our results showed
that the protein and mRNA expression levels of heparanase
and VEGF were significantly increased in OIR retinas. These
findings suggest that heparanase expression is upregulated by
oxygen overexposure and has a close relationship with the
VEGF  level  in  OIR  retinal  vascular  endothelial  cells.
Therefore, heparanase may be involved in the angiogenic
responses of OIR mice via promoting VEGF expression.
Our study showed that the expression of heparanase and
VEGF can be significantly decreased by PI-88 in OIR mice.
Furthermore, PI-88 decreased the expression of heparanase in
Group B and access to the expression of heparanase in Group
Figure 3. The effects of heparanase and
vascular  endothelial  growth  factor
(VEGF)  mRNA  expression  levels  on
oxygen-induced retinopathy (OIR) mice
and normal mice were as follows. A:
The  mRNA  expression  level  of
heparanase increased 1.71 fold in Group
B compared with Group A (p<0.0001)
but decreased 2.18 fold in PI-88–treated
mice  compared  with  the  group  B
(p<0.0001).  There  were  significant
differences  in  heparanase  expression
among the three groups (p<0.0001). B:
The mRNA expression level of vascular
endothelial  growth  factor  (VEGF)
increased  4.34  fold  in  Group  B
compared with Group A (p<0.0001) but
decreased  2.00  fold  in
phosphomannopentaose sulfate (PI-88)
treated mice compared with Group B
(p<0.0001).  There  were  significant
differences in VEGF expression among
the three groups (p<0.0001).
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1654A. Thus, PI-88 can decrease the expression of heparanase that
it has increased due to oxygen induction. PI-88 is a mixture
of highly sulfated oligosaccharides derived from the yeast
Pichia (Hansenula) holstii NRRL Y-2488 and is a potent
inhibitor  of  heparanase  [13,40,41].  PI-88  shows
antiangiogenic  activity  in  vitro  and  in  vivo,  which  is
attributable  to  three  known  mechanisms:  1)  inhibition  of
heparanase,  an  endoglycosidase  that  releases  VEGF  and
active  complexes  of  fibroblast  growth  factor  by  cleaving
heparan  sulfate  proteoglycans  in  blood  vessel  basement
membranes and the extracellular matrix; 2) direct inhibition
of the binding of heparan sulfate to VEGF and fibroblast
growth factor; and 3) stimulation of the release of tissue factor
pathway  inhibitor,  an  endogenous  antiangiogenic  protein
[13,42,43]. In this study, treatment with PI-88 resulted in a
decrease  in  the  expression  of  VEGF  and  heparanase.
Together,  these  results  indicate  the  decreased  VEGF
expression  may  be  due  to  the  inhibition  of  heparanase
expression by PI-88 treatment.
In conclusion, our study, using the OIR mouse model,
suggested  that  heparanase  expression  is  upregulated  in
association  with  VEGF  expression  in  OIR  retinas,  and
inhibition  of  heparanase  expression  may  be  a  novel
therapeutic strategy for ROP. In a future study, we will focus
on the mechanisms of hypoxia in upstream regulatory factor
for  heparanase  expression,  and  shed  light  on  the  clinical
treatment of ROP.
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Figure 4. The effects of heparanase and vascular endothelial growth factor (VEGF) protein expression levels on three group mice were as
follows. A: It shows the expression of heparanase in the three groups by western blot. The band that represents the 50 kDa activated enzyme
was more intense in Group B than in Group A, and the level was decreased by phosphomannopentaose sulfate (PI-88) treatment. B: It shows
the expression of VEGF in the three groups by western blot. The band that represents the 50 kDa activated enzyme was more intense in Group
B than in Group A, and the level was decreased by PI-88 treatment. C: The protein expression level of Group B increased compared with
Group A. There was a significant difference in the heparanase expression between the groups (p<0.0001). D: The protein expression level in
Group B increased compared with Group A. There was a significant difference in the VEGF expression between the groups (p<0.0001).
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